Versions :<12345Live>
Snapshot 2:Tue, Jul 23, 2024 7:46:56 PM GMT last edited by kiera22

HIV ‘vaccine’ could be made for just $40 a year per patient

HIV ‘vaccine’ could be made for just $40 a year per patient

    Image copyright: Wikimedia Commons

    The Spin

    It is still to early for Gilead to be able to predict what the cost for Lenacapavir as a PrEP will be. The research presented on Tuesday has not been peer reviewed, and thus while it is hopeful, it should not be given too much weight. Despite this, Gilead is working to ensure that the drug will be widely accessible in the future.


    Articles on this story

    Sign Up for Our Free Newsletters
    Sign Up for Our Free Newsletters

    Sign Up!
    Sign Up Now!